Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

Marso, Steven; Poulter, Neil; Nissen, Steven; Nauck, Michael; Zinman, Bernard; Daniels, Gilbert; Pocock, Stuart; Steinberg, William; Bergenstal, Richard; Mann, Johannes; Ravn, Lasse; Frandsen, Kirstine; Moses, Alan; Buse, John

doi:10.1016/j.ahj.2013.07.012

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

Atıf İçin Kopyala

Marso S. P., Poulter N. R., Nissen S. E., Nauck M. A., Zinman B., Daniels G. H., ...Daha Fazla

AMERICAN HEART JOURNAL, cilt.166, sa.5, ss.823-835, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 166 Sayı: 5
Basım Tarihi: 2013
Doi Numarası: 10.1016/j.ahj.2013.07.012
Dergi Adı: AMERICAN HEART JOURNAL
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.823-835
Akdeniz Üniversitesi Adresli: Hayır

Özet

Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk for a broad range of adverse cardiovascular outcomes including coronary heart disease, stroke, and cardiovascular death. Liraglutide is a human glucagon-like peptide receptor analog approved for use in patients with type 2 diabetes mellitus (T2DM).